GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shanghai RAAS Blood Products Co 002252.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

4.91

-0.61%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Shanghai RAAS Blood Products Co

Its shares trade on Shenzhen under the ticker 002252.SZ. It has been listed since 23 June 2008. In the fiscal year to 31 December 2025, it reported revenue of CN¥7.35bn and net income of CN¥1.58bn. At that date it held total assets of CN¥37.80bn and shareholders' equity of CN¥32.46bn.

Shanghai RAAS Blood Products Co., Ltd. engages in the research, development, production, and sale of blood products. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2008-06-23. The firm's main products include human albumin and human immunoglobulin for intravenous injection, human coagulation factors and others. The firm is also engaged in the distribution of Chinese medicine products and foods. The firm distributes its products within domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
23 Jun 2008
Employees
3,121

Leadership

Pay as last reported

  • Ms. Lixia TanChairman of the Board, since 2024
  • Mr. Jun XuVice Chairman of the Board, General Manager, since 2012CN¥6.5m
  • Mr. Leqi ChenFinance DirectorCN¥3.7m
  • Mr. Zheng LiuDeputy General Manager, Secretary of the BoardCN¥4.3m
  • Mr. Qinbing HuangDeputy General Manager
  • Mr. Hui LuDeputy General ManagerCN¥4.2m
  • Mr. Jihui ShenDeputy General ManagerCN¥4.2m
  • Ms. Zhengmin SongDeputy General ManagerCN¥4.2m
  • Ms. Ying GongDirector
  • Mr. Congqi GuDirector
  • Ms. Qian LeiDirector
  • Mr. Amarant Martinez CarrioDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
87
Environment
92
Social
81
Governance
88
Direct emissions (scope 1)
7,454.04 t
Energy emissions (scope 2)
32,485.48 t
Women in the workforce
54%
Carbon reduction policy
Yes
Human rights policy
Yes

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Shanghai with 3,121 employees
  • Produces human albumin and human immunoglobulin for intravenous injection
  • Distributes products domestically and internationally

Weaknesses

  • Relies on blood products which may face regulatory challenges
  • Dependent on domestic market for distribution
  • Engages in distribution of Chinese medicine products and foods which may dilute core focus

Opportunities

  • Expansion into overseas markets for blood products
  • Growth in demand for human coagulation factors
  • Potential for increased sales of human albumin

Threats

  • Regulatory scrutiny on blood product manufacturing
  • Competition from other biotechnology firms
  • Economic downturn affecting healthcare spending

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.